Frost & Sullivan Independent Equity Research
Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85
![kadimastem kadimastem](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/kadimastem-nx7oemt1c8wss047nf483o5eheckep4vzxb2tdiv9y.jpg)
Company: Kadimastem
Sector: Biotechnology
Report type: Initiation of Coverage
Published on: 12 June, 2018